EU and US could reach trade deal this weekend - Reuters
Cantor Fitzgerald maintained its Overweight rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) stock on Friday. According to InvestingPro data, analyst targets for ACAD range from $15 to $37, with the stock currently trading at $21.74. The company’s strong financial health score of "GREAT" and 44% return over the past year support the bullish outlook. The research firm highlighted three key growth drivers for the company’s Daybue medication in its analysis.
The first growth driver identified is Acadia’s recent 30% expansion of its field force, with the impact expected to materialize in the second half of 2025. This strategic workforce increase aims to boost the market presence of Daybue, one of the company’s leading products. The expansion comes as ACAD demonstrates strong revenue growth of 22.4% and maintains healthy profitability with nearly $1 billion in trailing twelve-month revenue.
Messaging on Daybue’s efficacy represents the second growth driver for Acadia, according to Cantor Fitzgerald. The third factor is the company’s focus on reinforcing management of gastrointestinal side effects related to the medication.
The research firm noted that long-term persistence, compliance to dose, and the number of active patients remain important metrics that are being carefully monitored for Daybue’s performance in the market.
Acadia Pharmaceuticals has positioned these three elements as central to its growth strategy for Daybue as it continues to expand the medication’s market presence and patient adoption. For deeper insights into ACAD’s growth potential and comprehensive financial analysis, including 12 additional ProTips, explore the full research report available on InvestingPro.
In other recent news, Acadia Pharmaceuticals Inc. has achieved a significant legal victory as the U.S. Court of Appeals for the Federal Circuit upheld the validity of the ’740 composition of matter patent for NUPLAZID, extending its protection until 2030. This decision follows earlier favorable outcomes for Acadia, including the affirmation of the ’721 formulation patent, which secures protection until 2038. Analysts from JPMorgan have responded by increasing Acadia’s stock price target to $30, citing confidence in the company’s legal standing and the extended exclusivity of NUPLAZID. Similarly, BofA Securities raised its price target to $23, maintaining a Neutral rating, and highlighted the potential for Acadia’s future growth. Additionally, Acadia held its 2025 Annual Meeting of Stockholders, where three Class III directors were elected, and Ernst & Young LLP was ratified as the independent registered public accounting firm. The company also received stockholder approval for executive compensation. These developments reflect Acadia’s ongoing focus on protecting its intellectual property and managing corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.